Literature DB >> 11072207

Cervical cancer screening in France.

P Schaffer1, H Sancho-Garnier, M Fender, P Dellenbach, J P Carbillet, E Monnet, G P Gauthier, A Garnier.   

Abstract

In France, as in other European countries the incidence and mortality rates of carcinoma of the cervix uteri indicate a clear decrease in invasive cancers. Opportunistic screening has spread and, presently, approximately 60% of the female population undergo a regular cytological test. This rate increases up to 80% in the younger age groups and decreases to 20% after the age of 60 years. In 1990, intervention procedures were defined at a consensus conference; the major recommendations were to screen all women exclusively by cervical smears, for ages 25-65 years over a 3-year period. Guidelines on the quality control of cervical smear taking and reading were published by the national agency of evaluation of health intervention (ANAES). Since 1990, four population-based, organised pilot programmes, have been implemented in Isère. Doubs, Bas-Rhin and Martinique. These programmes evaluate the participation rate (from approximately 20-80% depending upon the age and the geographical area), the rate of abnormal tests (0.2-3%), according to the laboratories, the cancer detection rate (0.04%-0.15%) and some other quality indicators. Recently (November 1998) a law was passed stipulating that the screening test will be free of charge when performed in agreement with the national recommendations. A specific organisation for cytological quality control will be implemented. An effort to better identify and to include the screening process the women in the population who are not yet participating has to be made.

Entities:  

Mesh:

Year:  2000        PMID: 11072207     DOI: 10.1016/s0959-8049(00)00312-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996.

Authors:  Edward Ng; Russell Wilkins; Michael Fung Kee Fung; Jean-Marie Berthelot
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

2.  Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.

Authors:  Alpana Sharma; Medha Rajappa; Alpana Saxena; Manoj Sharma
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia.

Authors:  N Reesink-Peters; M N Helder; G B A Wisman; A J Knol; S Koopmans; H M Boezen; E Schuuring; H Hollema; E G E de Vries; S de Jong; A G J van der Zee
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

4.  Evidence for cervical cancer mortality with screening program in Taiwan, 1981-2010: age-period-cohort model.

Authors:  Shih-Yung Su; Jing-Yang Huang; Chien-Chang Ho; Yung-Po Liaw
Journal:  BMC Public Health       Date:  2013-01-08       Impact factor: 3.295

5.  A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Authors:  Nadia Demarteau; Bruno Detournay; Bertrand Tehard; Abdelkader El Hasnaoui; Baudouin Standaert
Journal:  Int J Public Health       Date:  2010-11-26       Impact factor: 3.380

6.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.

Authors:  I H-I Chow; C-H Tang; S-L You; C-H Liao; T-Y Chu; C-J Chen; C-A Chen; R-F Pwu
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

7.  The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.

Authors:  Andrzej Nowakowski; Marek Cybulski; Andrzej Śliwczyński; Arkadiusz Chil; Zbigniew Teter; Przemysław Seroczyński; Marc Arbyn; Ahti Anttila
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

8.  General practitioners who never perform Pap smear: the medical offer and the socio-economic context around their office could limit their involvement in cervical cancer screening.

Authors:  Chiara Maj; Lorraine Poncet; Henri Panjo; Arnaud Gautier; Pierre Chauvin; Gwenn Menvielle; Emmanuelle Cadot; Virginie Ringa; Laurent Rigal
Journal:  BMC Fam Pract       Date:  2019-08-15       Impact factor: 2.497

9.  Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe.

Authors:  Stanie Gaete; Aviane Auguste; Bernard Bhakkan; Jessica Peruvien; Cecile Herrmann-Storck; Youri Socrier; Abdoulaye Diedhiou; Jacqueline Deloumeaux
Journal:  BMC Cancer       Date:  2021-03-16       Impact factor: 4.430

10.  Cervical cancer screening programmes and policies in 18 European countries.

Authors:  A Anttila; G Ronco; G Clifford; F Bray; M Hakama; M Arbyn; E Weiderpass
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.